RayBiotech, Inc. and the combined genotyping core facility for Oslo University Hospital and the University of Oslo, located at the Institute for Cancer Research, announced the execution of an agreement to collaborate for the implementation of antibody-based sample analysis services. Under the terms of the agreement, the combined core facility will provide a comprehensive service utilizing RayBiotech's proprietary antibody arrays for the high-throughput detection and analysis of protein biomarkers in biological samples. The service program will target academic and industrial research clients having a need for fully quantifiable biomarker analysis.
RayBiotech's Quantibody® array platform, which delivers high throughput quantitative expression profiles, will be a key component of the core facility's service program. Potential biomarkers will include cytokines, growth factors, and other secreted factors related to cancer and other complex diseases. The service will be applicable to both human specimens and animal models such as mice, rats, pigs, and primates.
RayBiotech will work closely with the Institute for Cancer Research, the Oslo University Hospital and the University of Oslo to provide all the necessary products, technical expertise, and marketing and sales support needed to implement the services program. Financial terms were not disclosed.
Commenting on the collaboration, RayBiotech's President, COO and Co-founder, Rani Huang, said, "We are delighted that the Institute for Cancer Research, Norwegian Radium Hospital has partnered with RayBiotech to implement antibody array testing services. We've had a long-standing relationship with the University of Oslo and are pleased to initiate this collaboration with such a world-renowned research institution. It is our expectation that these antibody array testing services will help researchers to identify new molecular and biochemical pathways and promote drug discovery as well as drug target validation."
Professor Eivind Hovig, head of the genotyping core facility, and head of the bioinformatics core facility, stated, "We have come to recognize that the antibody array products provided by RayBiotech provide excellent possibilities for biomarker screening, and we see that the quality and breadth of the products are valuable additions to ongoing research at our institutions. We are currently undertaking large studies involving several groups across a number of research disciplines based on RayBiotech array products. We are very happy with this partnership, as we foresee increased usage of these very useful products in the near future."
Study shows cannabis as a genotoxic substance with cancer risks